Introduction
Basal cell carcinoma is the most common skin cancer in humans in the United States with an estimated incidence of approximately 1 million new cases per year. 1 Although metastases rarely occur, the tumor cells are locally invasive, destroy surrounding tissue and cause substantial morbidity. Cell-mediated immunity appears to be important in the pathogenesis of BCC and the immune system may contribute to protection in this disease. Results from several clinical trials indicate that interferon can be effective in the treatment of basal cell carcinoma. [2] [3] [4] [5] [6] [7] [8] Multiple intralesional injections of IFN-␣2 over a 3-week period induced overall remission rates of 70 to 100%. 3, 9 Increased numbers of CD4 + T cells surrounding the BCC infiltrating tumor island in the dermis have been observed after intralesional IFN-␣ therapy. [10] [11] [12] It has also been shown previously that the number of antigenpresenting cells (APC) expressing HLA-DR and CD1a is reduced in BCC, compared with normal human skin. 13 It is therefore likely that IFN-␣ therapy may render local APC more effective in triggering the immune response against tumor cells. 2, 14, 15 Tumor regression upon IFN-␣ injection may also involve non-immune mechanisms that contribute to anti-tumor effects. For example, Buechner et al 16 recently described that the injection of IFN-␣ induces the CD95 receptor which then interacts with the already expressed CD95 ligand on the cell surface. Presumably, this interaction would promote apoptosis of BCC cells.
Gene therapy has potential applicability to the treatment of neoplastic disease in humans. BCC is an acquired disease related to sun exposure and is accessible for both injectable and topical gene delivery, thus representing an excellent target of study. Successful transfer and expression of genes by injection into human skin tumors such as melanoma have previously been reported, [17] [18] [19] but this approach has not been well-explored for BCC. Potentially, delivery of appropriate genes into BCC could be used to achieve sustained protein expression locally, thus offering an alternative to surgery or multiple injections of recombinant IFN-␣2. In this report, we describe gene delivery using liposome-mediated gene transfer. An animal model was established in which BCC were transplanted on to SCID mice, gene delivery was optimized, and biological responses were assessed. Taken together, we show that intralesional delivery of DNA encoding IFN-␣2 has prolonged expression compared with injection of recombinant IFN-␣2 protein and affects BCC growth.
Results

Generation of a BCC mouse model
Tumors with a superficial clinical pattern and greater than 1 cm 2 were selected. After surgical removal of human basal cell carcinomas, tumors were orthotopically transplanted to the backs of SCID mice. Tumor appearance was normal and showed no signs of remission for up to 3 weeks or more after transplantation (Figure 1a ). Of 25 BCC xenografts, 20 (80%) that were left untreated during the experiment retained the clinical appearance of a slow growing superficial erythromatous lichenoid papule or plaque, often seen with a few dilated superficial vessels (Figure 1a , arrow). Histologically the BCCs were well-vascularized, and the tumor cells resembled those of the basal layer of the epidermis with a sparse cytoplasm and darkly staining nuclei (Figure 1b , arrow). In some biopsies there was a marginal palisade of tumor cells. After 21 days, different DNAs were injected intralesionally and the effects of gene transfer were analyzed.
Optimization of plasmid gene transfer
Before transfection of DNA encoding IFN-␣ into BCC, optimization of gene transfer using the CAT expression vector, CMV-CAT, as a reporter gene was performed. BCC grafted on to SCID mice were used to optimize gene delivery. Different amounts of plasmid DNA or DNA lipoplexes were injected intratumorally, and CAT activity was determined. Cationic liposome-mediated gene transfer has been used previously to transduce numerous primary animal and tumor cells successfully, 18, 19 but this method has not been evaluated in BCC. The inclusion of DMRIE/DOPE, which allows formation of DNA lipoplexes, increased detectable CAT activity 60-fold ( Figure  2a ). An increase in DNA above 150 g with a constant lipid concentration reduced CAT activity (Figure 2b) , possibly due to formation of suboptimal, inactive complexes, as previously described. The optimal amount of DNA and liposome for the transfection was found to be 150 g (1.5 mg/ml, 2.8 mm nucleotides) and 450 g (4.5 mg/ml, 3.8 mm) of liposome. The optimal molar ratio of lipid to nucleotide was therefore 1.35. This molar ratio was similar to that used previously in other tissues. 20 CAT activity was detectable for up to 6 days after injection (Figure 2c) .
To define the distribution of the gene expression in BCC, the heat stable isoform of human placental alkaline phosphatase (hpAP) reporter under control of the same regulatory element, the CMV enhancer/promoter, was injected intratumorally, and gene expression was analyzed histologically 2 days later. Histochemical staining was observed predominantly in the epidermal layer of the lesion (Figure 3 ). When naked DNA was injected, a different pattern of expression, consisting of weak diffuse staining primarily in the dermis, was noted ( Figure 3 , middle panel). With DNA lipoplexes, recombinant hpAP activity was increased, as seen with the CAT reporter, and was highest in the deepest layers of the epidermis, including stratum spinosum and stratum basalis ( Figure  3 , left panel). By using simultaneous staining with the NBT assay and an anti-CD1a FITC antibody, we determined that the gene product was not expressed in epidermal Langerhans cells (data not shown). At the present time, it does not appear that the gene product is expressed by a specific subset of cells in the skin; however, it appears that DNA lipoplexes promote gene expression in the basal keratinocyte, and possibly other cells in this region.
Biological activity of different interferon subtypes in vitro
The biological effects of IFN protein on BCC have been previously reported. 3, 9 To analyze the effects of recombinant IFN gene expression, cDNAs encoding human IFN subtypes ␣2, ␣4, ␣7, ⍀1, and mouse IFN ␣2 and ␣7 were prepared by RT-PCR from peripheral blood mononuclear cells (PBMC) and inserted into the same CMV-regulated eukaryotic expression vector. These plasmids were transiently transfected into human melanoma cells, which are not responsive to IFN, and supernatants were analyzed for their biological activity with an interferon-responsive element (IRE) reporter, IRE-CAT, in Jurkat T-leukemia cells. All human IFN subtypes, but not mouse IFN or a plasmid control, were active in this assay (Figure 4a) , consistent with their known species specificity.
32,33 Background staining (left panel), injection of DNA only (middle panel) or DNA lipoplex injection (right panel) was compared. Dashed line defines the border between dermis (D) and epidermis (E).
Figure 4 Biological activity of different IFN subtypes in vitro. DNA encoding different interferon subtypes was transiently transfected into a human melanoma cell line, UM316, and supernatant collected 48 h after transfection. (a) Jurkat T-leukemia cells were transfected with IRE-CAT
The stability of IFN activity was characterized as a potential indicator of its effect in vivo. The stability assays were performed to explore whether the commonly used recombinant IFN-␣2 is the most stable in comparison to others. IFN-containing supernatants were incubated at 42°C for extended times and their biologic activity analyzed using the IRE reporter assay. After incubation at 42°C for 5 days, IFN-␣2 and IFN-␣4 retained higher activity than IFN-␣7 and IFN-⍀1 (Figure 4b ), though the magnitude of these differences was not great. Because only IFN-␣2 is available as a purified recombinant protein, we therefore focused on IFN-␣2 for further studies of intralesional injections.
Comparison of biological activity of recombinant IFN-␣2 protein and vector encoded IFN-␣2 in vivo
We next compared the effects of vector-expressed IFN-␣ and recombinant protein in BCC transplanted to SCID mice. Plasmid DNA encoding human IFN-␣2, or a negative control plasmid, was injected intralesionally as a DNA lipoplex. In comparison, clinical grade recombinant IFN-␣2 (10 5 units, Schering Plough, Madison, WI, USA) was injected. Immunohistochemical analysis of HLA-DR expression was performed on specimens removed 2 and 5 days after injection ( Figure 5 ). BCC injected with recombinant IFN showed a marked increase in HLA-DR expression in the dermis after 2 days which had diminished by 5 days ( Figure 5 , middle panel), likely reflecting the known rapid degradation of the recombinant protein in vivo. Lesions injected with vector-encoded IFN-␣2 showed a more modest increase in HLA-DR expression after 2 days, but higher expression than the recombinant protein after 5 days, suggesting that vector expression of IFN-␣2 sustained interferon secretion locally ( Figure 5 , compare middle panel to left panel). Xenografts injected with a control DNA showed no increase in HLA-DR and CD1a expression, indicating that the injection of the DNA lipoplex per se did not induce HLA-DR and CD1a expression ( Figure 5, left panel) . Untreated xenografts showed no increase in HLA-DR and CD1a expression (data not shown). In contrast to IFN-␣2, IFN-␣4 did not induce the expression of the HLA-DR in the dermis (data not shown).
Regression of BCCs after injection of DNA lipoplexes expressing IFN-␣2
To test the effect of IFN-␣2 vector on tumor growth, DNA lipoplexes encoding IFN-␣2 or a negative control plasmid were injected into BCC implants. Six days after intralesional injection, tumor regression was observed in lesions injected with DNA lipoplex expressing IFN-␣2, but no regression was observed with the negative control DNA lipoplex (Table 1) , indicating the expression of the IFN-␣2 gene, rather than a nonspecific DNA lipoplex or an adjuvant effect, was necessary for regression.
Discussion
There were several notable findings in this report, including the relatively high rate of engraftment and stable 
The tumor mass of each of the transplanted BCCs was estimated by two independent investigators using a semi-quantitative 3-point scale: 3 = clinically resembling BCC (lichenoid papule or plaque with visible dilated superficial vessels); 2 = moderate involvement (moderate infiltration and scale and one of the signs in 3); 1 = slight involvement (infiltration, scale); 0 = complete remission.
phenotype for superficial BCC (20 of 25; 80%), the optimization of plasmid DNA gene transfer encoding IFN-␣, and prolonged IFN-␣2 protein production with subsequent regression of engrafted BCCs. Previous investigators attempting to engraft human BCCs on to immunodeficient mice encountered significant difficulty using athymic (nude) mice. 21, 22 Without additional immunosuppression in these animal models, less than 50% longterm survival of superficial grafts was observed. 21, 22 When beige nude mice were used as recipients, the persistence of tumor increased to over 75%. 23 By using SCID mice, this current report confirms and extends these previous reports highlighting the importance of deletion of both functional T cells and B cell function. The thicker, better vascularized skin of SCID mice over nude mice may have also contributed to the higher rates of engraftment and stability of this tumor.
Having established the utility of the human skin-SCID mouse chimeric animal model, we next applied gene transfer technology to the engrafted human skin. It was clearly established that gene transfer was significantly increased by using DNA liposome complexes (lipoplexes). These optimization protocols led to consistently high and sustained protein levels of IFN-␣2 that produced complete remission of tumor cells in each of three different BCCs examined.
A theoretical advantage of local gene delivery as a treatment modality is its potential to sustain expression of therapeutic genes locally. To address this need, we have begun to develop methods to enhance gene expression in a disease model where local protein production has provided clinical efficacy. 3, 9 Recombinant IFN-␣ has been used with some success in BCC, but is often limited by the need to repeat injections required to sustain durable remissions. In this study, we have analyzed the potential of gene delivery to provide for more sustained IFN production locally. Gene delivery has been optimized using a novel xenograft with intralesional injection of DNA liposome complexes. Expression of IFN-␣2 stimulated HLA-DR expression in BCC and facilitated local regression.
IFN-␣ exerts several potential antitumor effects, including activation of immune cells, inhibition of cell proliferation, induction of cell differentiation, increased class I major histocompatibility complex antigen expression, inhibition of angiogenesis, and establishment of a T helper (Th1)-type response. [24] [25] [26] Horton et al 27 showed recently the antitumor effect of IFN-␣ on primary and metastatic tumors after intramuscular injection. The mechanism of the antitumor effect of IFN-␣ appeared to involve primarily the induction of a Th1-type immune response. Buechner et al 2 described recently that the intralesional treatment of BCC by IFN-␣ is mediated by a nonimmune mechanism involving CD95-CD95 ligand induced suicide.
In this report, we showed that the expression of recombinant genes such as IFN after intralesional injection is sufficient to induce antitumor effects known to be associated with IFNs. It was shown that DNA or DNA lipoplexes can mediate gene transfer into tissues and facilitate gene expression locally at higher concentrations. 17, 18, 28 The expression of IFNs can, in the case of BCC, be achieved locally and may help to avoid systemic effects. Because these studies were performed in immunodeficient recipients, the mechanism was presumably nonimmune. Such genes encoding anti-proliferative genes or inhibitors of angiogenesis which are locally effective could complement systemic immunologic approaches. We believe that IFN-␣ exerts several potential antitumor effects including activation of immmunocytes, establishment of a Th1 response, nonimmune mechanisms involving CD95-CD95L, inhibition of cell proliferation and induction of differentiation. We have used a semiquantitative scale to estimate the tumor mass of each individual graft during and after injection of IFN-␣. It should be pointed out that apoptosis may be directly or indirectly contributed to the aforementioned effects.
Substantial advances in the development of expression vectors and delivery systems have occurred in the last few years. In this study, DNA lipoplexes were utilized as a nonviral gene delivery vector. Direct injection of plasmid DNA is especially suitable for the skin as it is easily accessible. Nonviral gene delivery, and subsequent uptake by cells in vivo, has been described and proven to be a valid methodological approach. 17, 18 The advantage of a nonviral gene transfer is that the different components are stored stably for long periods of time and do not represent a significant biological hazard. This approach can potentially also be applied to other skin diseases. Taken together, these data suggest that direct gene transfer using DNA lipoplexes warrants further exploration in BCC.
Materials and methods
Patients
Basal cell carcinomas were obtained from both male and female patients undergoing Mohs surgical excision (n = 25, aged 38-65). Tumors were selected with size greater than 1 cm 2 with a superficial clinical pattern. Two nodular tumors were also included early in the study. As per standard operating procedure for the Mohs technique, all gross tumor was completely excised in a debulking stage, using cold steel.
The tumor and surrounding skin was defined and infiltrated with 1% lidocaine with epinephrine 1:400 000. All gross tumor was completely excised in a debulking stage using a Gillette (Boston, MA, USA) blue blade or cold steel, with peripheral margins located at the tumornormal skin junction to the superficial reticular dermis as the deep margin. The tumor was transferred to PBS supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 1 mg/ml gentamicin (GIBCO BRL, Grand Island, NY, USA) and immediately transferred to the freezer at 4°C until transplanted (Ͻ36 h). Immediately before orthotopical transplantation on to the flank area of 7-8-week-old anesthetized (intraperitoneal injection of 1.56 mg phenobarbitol) SCID mice (Taconic Farms, Germantown, NY, USA) the excisional margins were cut off the tumors. The grafts were sutured to each SCID mouse with absorbable 6-0 Rapide suture (Ethicon, Somerville, NJ, USA) and covered with Xeroform dressings (Kendall, Mansfield, MA, USA). Dressings were removed 1 week later, and animals were maintained in pathogen-free conditions throughout the study. Lipoplexes were diluted in sterile Ringer's lactate (300 l) 22 ± 4 days after transplantation, and injected intradermally into the xenograft using a 30-gauge needle (Becton Dickinson, Franklin Lakes, NJ, USA). Within 1-2 weeks the mice were killed by CO 2 asphyxiation, and 4 mm punch biopsies (Acu Punch; Acuderm, Ft Lauderdale, FL, USA) were obtained from each xenograft. Biopsies were fixed in 10% neutralbuffered formalin for paraffin embedding, and/or transferred to cryotubes and snap frozen in liquid nitrogen, and stored at −80°C.
Preparation of DNA liposome complexes Batch preparations of the cationic liposome (dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE)/dioleoyl phosphatidylethanolamine (DOPE) were kindly provided by Vical, San Diego, CA, USA. For gene transfer, 10 min before delivery, 0.1 ml of plasmid DNA (0.3-2.1 mg/ml) in lactated Ringer's solution was added to 0.1 ml of DMRIE/DOPE liposome solution with a constant molar ratio of lipids:nucleotides of 1.35.
Immunohistochemistry of human skin grafts
Cryostat tissue sections, 5 m thick, were fixed with acetone, and immunostaining performed for HLA-DR and CD1a antigens. These proteins were visualized using biotinylated goat anti-mouse F(ab) 2 fragment (DAKO, Carpinteria, CA, USA), streptavidin-alkaline phosphatase (DAKO) and Fast-Red chromogen (DAKO). Formalin fixed, paraffin embedded samples were dewaxed in xylene and ethanol and rehydrated for hematoxylin and eosin (HE) staining.
Antibodies
Antibodies were purchased and used under the following conditions: HLA-DR (Becton Dickinson, 1:10), CD1a (DAKO, 1:20), biotinylated goat anti-mouse F(ab) 2 fragment (DAKO, 1:300), Steptavidin-AP (DAKO, 1:150).
Culture conditions UM316 and Jurkat T-cells were cultured at 37°C and 5% CO 2 in DMEM (Irvine Scientific, Santa Ana, CA, USA), supplemented with 10% FCS and 5% FCS heat inactivated (BioWhittaker, Walkersville, MD, USA), 2 mm l-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin (Irvine Scientific).
CAT assay
The CAT assay was performed as described. 29, 30 Briefly, BCC were homogenized in 0.25 m Tris pH 7.8 cells using microtubes and pellet pestles from PGC Scientific (Gaithersburg, MD, USA). Cells were disrupted by freeze/thawing in dry ice and ethanol three times and heated for 10 min at 65°C. To detect pCMV-CAT in cell cultures, cells (1-10 × 10 6 ) were washed twice in PBS, resuspended in 0.25 m Tris pH 7.8, and disrupted by freeze/thawing in dry ice and ethanol three times. The extract (50-150 g protein) was incubated with 750 mm Tris pH 7.8, 14 C-labeled chloramphenicol and acetyl coenzyme A for 2-4 h at 37°C. Amounts were standardized so that equal protein concentrations (which corresponded to similar numbers of transfected cells) were used in each experiment.
Plasmids and IFN subtypes pCMV-CAT plasmid was constructed as described previously. 31 pCMV-AP plasmid was described previously. 20 The cDNA for the different IFN subtypes was generated by RT-PCR using for human IFN-␣2: GCTAGGATAT CACCATGGCCTTGACCTTTGCTTTAC and ATCGGA TCCTCATTCCTTACTTCTTAAACTTTC, for human IFN-␣4 GCTAAGATATCACCATGGCCCTGTCCTTTT CTTTAC and ATCGGATCCTCAATCCTTCCTCCTTA ATCTTTTTTG, for human IFN-␣7 GCTAGGATATCAC CATGGCCCGGTCCTTTTCTTTAC and ATCGGATCC TCAATCCTTCCTCCTTAATCC, for human IFN-⍀1 GCTAGGATATCACCATGGCCCTCCTGTTCCCTCTAC and ATCGGATCCTCAAGATGAGCCCAGGTCTATA TC, for mouse IFN-␣2 ATCGGATCCTCACTCCTT CTCTTCACTCAGTC and GCTAGGATATCACCATGG CTAGACTCTGTGCTTTCC and for mouse IFN-␣7 GCTAGGATATCACCATGGCTAGGAAGGATCAGGA CC and ATCGGATCCTCACTCCTTCTTCTCACTCAG TCTTGCC and total RNA from human or mouse PBMC. The PCR products were digested with EcoRV and BamHI and ligated into the VR1332 31 vector which had been cut with the same enzymes. IRE-CAT with the CAT reporter gene under the control of the interferon responsible element has been previously described. 8 
